MediSix Therapeutics Signs Exclusive Licensing Agreement with the National University of SingaporeMarkets InsiderLightstone Singapore, L.P. and Professor Dario Campana from the Department of Pediatrics, NUS Yong Loo Lin School of Medicine founded Medi… Continue reading
Modulating T-cell metabolism uncovers new technology for enhancing immunotherapyMedical XpressT lymphocytes found in tumors and implicated in killing tumor cells cope with the shortage of oxygen and nutrients in the tumor microenvironment by using fat … Continue reading
Los Angeles Business JournalUCLA Launches First-of-Its-Kind Stem Cell Trial to Combat CancerLos Angeles Business JournalScientists at UCLA have launched the first genetically engineered blood stem cell clinical trial to fight cancer thanks to $20 milli… Continue reading
The San Diego Union-TribuneAntibody-created stem cells may have superior propertiesThe San Diego Union-TribuneHuman induced pluripotent stem (iPS) cell colonies created from adult skin cells. Blue represents all DNA. Green and red indicates cell surfac… Continue reading
New York Times |
New Gene–Therapy Treatments Will Carry Whopping Price Tags
New York Times The first gene therapy treatment in the United States was approved recently by the Food and Drug Administration, heralding a new era in medicine that is coming faster than most realize — and that perhaps few can afford. The treatment, Kymriah, made by … A new cancer drug may be the first in a line of revolutionary treatmentsChicago Tribune |
OncLive |
Nivolumab/Ipilimumab Improves Survival Versus Sunitinib in mRCC
OncLive In those with PD-L1 expression ≥1%, the Median PFS was significantly longer with the immunotherapy combination than with sunitinib (22.9 vs 5.9 months; HR, 0.48; P = .0003). Those with PD-L1 expression <1% did not benefit from the combination (HR, … Nivolumab cuts relapse by one third compared to IpilimumabEuropean Pharmaceutical Review Combination targeted adjuvant therapy doubles relapse-free survival in stage III melanomaMedical Xpress |
|
UCLA opens first engineered blood stem cell clinical trial for cancers with the NY-ESO-1 tumor marker
Newswise (press release) Newswise — Scientists at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have initiated a phase 1 clinical trial to test a novel cancer treatment for certain kinds of cancers that have a specific tumor marker … |